Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study

CONCLUSIONS: Patients with metastatic lung cancer with Medicaid coverage were found to have exceedingly low biomarker testing rates; only 57% had evidence of any biomarker testing. Although no consistent differences between Black and White races were identified, this study calls attention to care experienced by socioeconomically disadvantaged patients with metastatic lung cancer in the United States.PMID:38496377 | PMC:PMC10941001 | DOI:10.1016/j.jtocrr.2024.100643
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research